Welcome to Jiangxi Yuneng Pharmaceutical Co., Ltd.
    Your Position:Home > News Center
    1. China's raw material drug regulatory standards need to be in line with China and foreign countries

      [2019-03-11]

      In the pharmaceutical market, APIs play a vital role, and the efficacy in pharmaceutical manufacturing is irreplaceable. However, in the past few years, China’s negative growth in the export of bulk pharmaceuticals to the major markets in the United States was an ominous signal.

    2. The environmental protection pressure of raw material pharmaceutical companies has increased sharply

      [2019-03-11]

      At the beginning of 2015, the new Environmental Protection Law was officially implemented. This is the sword of Damocles hanging over the head of the company that has polluted emissions.

    3. Pharmaceutical and Biological Industry: Monthly Price of Major APIs

      [2019-03-11]

      In February, the price of vitamin varieties showed a differentiation. In February, the average transaction price of VE was 45 yuan/kg, down 4.12% from the previous month; the average transaction price of VA was 112 yuan/kg, down 4.05% from the previous month, and the latest transaction was 110 yuan/kg; the average price of VD32 was 135 yuan/kg, down from the previous month. 7.65%; the average tran

    4. The transfer of the API industry to the upstream of the industrial chain is inevitable

      [2019-03-11]

      In the international market, some of China's bulk APIs have a global market share of over 90%. However, the large scale of development does not mean that China is already a strong producer of APIs. On the contrary, China is still at the lowest stage of API production.

    5. International API market goes out of the wave curve

      [2019-03-11]

      According to a recent report issued by the International Association of Pharmaceutical Raw Materials Industry (CPA), based in Milan, Italy, the international API market has shown a “rising-slipping-re-rising” wave pattern over the past 10 years.

    6. The drug substance industry eliminates hidden dangers

      [2019-03-11]

      Continuously extending and shifting to the downstream supply chain, domestic deep processing capabilities are gradually increasing.

    7. The transformation of APIs depends on many factors. Innovation is the key.

      [2019-03-11]

      With the continuous upgrading of the development of the pharmaceutical industry at home and abroad, the export profits of bulk pharmaceutical raw materials in China have been greatly reduced, which has triggered a crisis in the development of the industry.

    8. Improving the domestic pharmaceutical innovation market system is the prerequisite for the transform

      [2019-03-11]

      Technological innovation in the API industry is a very complex system engineering innovation system involving pharmacy, chemistry, biology, informatics, engineering, mechanical technology and so on.

    9. China's hormonal API exports stepped into the normal trade track

      [2019-03-11]

      According to China Customs statistics, in 2014, the export value of hormonal APIs in China increased by 52.99% year-on-year, achieving the largest increase since the European debt crisis.

    10. Innovation in the API industry requires both corporate and government

      [2019-03-11]

      Technological innovation in the API industry is a very complex system engineering innovation system involving pharmacy, chemistry, biology, informatics, engineering, mechanical technology and so on.